Uveitis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 19 Jun 2026 04:02:51 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Uveitis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study to evaluate the safety of REGN7041 in adults with active noninfectious uveitis affecting the back of the eye. https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-of-regn7041-in-adults-with-active-noninfectious-uveitis-affecting-the-back-of-the-eye/ Wed, 29 Apr 2026 15:09:17 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-of-regn7041-in-adults-with-active-noninfectious-uveitis-affecting-the-back-of-the-eye/ This study focuses on individuals living with Noninfectious Uveitis affecting the posterior segment, which refers to the back part of the eye. This condition involves inflammation in the eye that is not caused by an infection. The investigation aims to evaluate the safety and how well the body tolerates the study drug.

The treatment being tested is an anti-CD3 monoclonal antibody called REGN7041. This medication is provided as a solution for injection and is administered via intravitreal use, which means the medicine is injected directly into the jelly-like substance inside the eye. Participants may receive either a single dose or repeated doses of this substance during the course of the study.

]]> Study on the Effects of Brepocitinib and Prednisone for Adults with Active Non-Infectious Uveitis https://clinicaltrials.eu/trial/study-on-the-effects-of-brepocitinib-and-prednisone-for-adults-with-active-non-infectious-uveitis/ Wed, 29 Apr 2026 15:02:39 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-brepocitinib-and-prednisone-for-adults-with-active-non-infectious-uveitis/ This clinical trial is focused on studying a condition called non-infectious uveitis, which is an inflammation inside the eye that is not caused by an infection. The study specifically looks at three types of this condition: intermediate uveitis, posterior uveitis, and panuveitis. The main treatment being tested in this study is a medication called brepocitinib, which is taken orally in the form of a tablet. The study also involves the use of a placebo tablet, which looks like the brepocitinib tablet but does not contain the active medication.

The purpose of the study is to evaluate how effective brepocitinib is in treating the inflammation associated with non-infectious uveitis. Participants in the study will be randomly assigned to receive either brepocitinib or a placebo. The study will last for a period of up to 96 weeks, during which participants will take the medication and attend regular check-ups to monitor their condition and any changes in their symptoms.

Throughout the study, doctors will closely observe the participants to see how well the treatment works and to ensure their safety. The study aims to provide valuable information on whether brepocitinib can help reduce the inflammation and improve the symptoms of non-infectious uveitis. This research could potentially lead to better treatment options for people living with this eye condition.

]]> Study on Izokibep for Patients with Non-infectious Uveitis https://clinicaltrials.eu/trial/study-on-izokibep-for-patients-with-non-infectious-uveitis/ Wed, 29 Apr 2026 15:00:30 +0000 https://clinicaltrials.eu/trial/study-on-izokibep-for-patients-with-non-infectious-uveitis/ This clinical trial is focused on studying a condition called non-infectious uveitis, which affects the middle, back, or entire eye. Uveitis is an inflammation of the eye that can cause redness, pain, and vision problems. The study is testing a new treatment called Izokibep, which is given as an injection under the skin. Izokibep is being compared to a placebo to see how well it works in treating this eye condition.

The purpose of the study is to evaluate the effectiveness and safety of Izokibep in people with non-infectious uveitis. Participants in the study will receive either Izokibep or a placebo and will be monitored over a period of time to see how their condition responds to the treatment. The study will last for up to 52 weeks, with regular check-ups to assess the health of the participants’ eyes and overall well-being.

Throughout the study, participants will be closely observed to track any changes in their condition and to ensure their safety. The main goal is to determine if Izokibep can help reduce the symptoms of uveitis and improve the quality of life for those affected by this condition. This research could lead to new treatment options for people living with non-infectious uveitis.

]]> Study on the Effectiveness and Safety of Tocilizumab and Adalimumab for Patients with Severe Uveitis in Behçet’s Disease https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-tocilizumab-and-adalimumab-for-patients-with-severe-uveitis-in-behcets-disease/ Wed, 29 Apr 2026 15:00:07 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-tocilizumab-and-adalimumab-for-patients-with-severe-uveitis-in-behcets-disease/ This clinical trial is focused on studying the treatment of a condition called severe uveitis in people with Behçet’s disease. Uveitis is an inflammation inside the eye that can lead to vision problems, and Behçet’s disease is a rare disorder that causes blood vessel inflammation throughout the body. The study will compare two treatments: tocilizumab and adalimumab. Tocilizumab is a medication given as an injection under the skin, and it works by blocking a protein in the body that can cause inflammation. Adalimumab is also an injection that helps reduce inflammation by targeting a specific protein involved in the body’s immune response.

The purpose of this study is to assess the benefits of tocilizumab compared to adalimumab in treating sight-threatening uveitis in Behçet’s disease. Participants in the study will receive either tocilizumab or adalimumab and will be monitored over a period of time to see how well the treatments work in reducing eye inflammation and improving vision. The study will also look at how these treatments affect the need for other medications, like corticosteroids, which are often used to control inflammation.

Throughout the study, participants will have regular check-ups to monitor their eye health and overall well-being. The study aims to provide valuable information on the effectiveness and safety of these treatments for people with severe uveitis due to Behçet’s disease. This research could help improve treatment options and outcomes for patients with this challenging condition.

]]> Study of Baricitinib and Adalimumab for Children Aged 2 to 17 with Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis https://clinicaltrials.eu/trial/study-of-baricitinib-and-adalimumab-for-children-aged-2-to-17-with-active-juvenile-idiopathic-arthritis-associated-uveitis-or-chronic-anterior-antinuclear-antibody-positive-uveitis/ Wed, 29 Apr 2026 14:48:02 +0000 https://clinicaltrials.eu/trial/study-of-baricitinib-and-adalimumab-for-children-aged-2-to-17-with-active-juvenile-idiopathic-arthritis-associated-uveitis-or-chronic-anterior-antinuclear-antibody-positive-uveitis/ This clinical trial is focused on studying the safety and effectiveness of the medication Baricitinib in children and teenagers aged 2 to less than 18 years who have active Juvenile Idiopathic Arthritis-associated Uveitis or chronic anterior antinuclear antibody-positive Uveitis. Uveitis is an inflammation of the middle layer of the eye, which can cause pain, redness, and vision problems. The study aims to determine if taking Baricitinib orally can help manage these conditions.

Participants in the study will receive Baricitinib, which is available in tablet form, and will be monitored over a period of time to assess its impact on their condition. The study will compare the effects of Baricitinib with those of other treatments, including a placebo, to evaluate its safety and effectiveness. The treatment period for Baricitinib can last up to 284 days, depending on the participant’s response to the medication.

The study is designed to observe changes in the level of eye inflammation, using criteria that measure the decrease in inflammation over time. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and to gather data on how well the treatment works. This research is important for understanding how Baricitinib can be used to help young patients with these specific types of Uveitis.

]]> Study on Methotrexate and Adalimumab for Non-Infectious Uveitis in Patients: Evaluating Effectiveness and Safety https://clinicaltrials.eu/trial/study-on-methotrexate-and-adalimumab-for-non-infectious-uveitis-in-patients-evaluating-effectiveness-and-safety/ Wed, 29 Apr 2026 14:30:11 +0000 https://clinicaltrials.eu/trial/study-on-methotrexate-and-adalimumab-for-non-infectious-uveitis-in-patients-evaluating-effectiveness-and-safety/ This clinical trial is focused on studying the effectiveness and safety of treatments for a condition called non-infectious uveitis. Uveitis is an inflammation of the middle layer of the eye, which can lead to vision problems. The study will explore the use of two medications, Adalimumab and Methotrexate, either on their own or in combination. Adalimumab is a type of medication known as an immunoglobulin, which helps to reduce inflammation by targeting specific proteins in the immune system. Methotrexate is a chemical medication that also helps to control inflammation and is often used in autoimmune diseases.

The purpose of this study is to compare how well patients respond to these treatments over a period of time. Participants will be randomly assigned to one of three groups: one group will receive Adalimumab, another will receive Methotrexate, and the third group will receive a combination of both medications. The study will last for up to 52 weeks, during which participants will have regular visits to monitor their response to the treatment. The goal is to see if the treatments can help maintain a good clinical response, which means reducing the symptoms of uveitis and preventing flare-ups of inflammation.

Throughout the study, participants will be closely monitored to ensure their safety and to assess the cost-effectiveness of the treatments. The study will also look at various aspects of the participants’ health and quality of life, such as changes in vision and any side effects experienced. By the end of the study, researchers hope to determine which treatment option is most effective for managing non-infectious uveitis.

]]> Study on the Effectiveness of Baricitinib for Patients with Refractory Non-Infectious Uveitis https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-baricitinib-for-patients-with-refractory-non-infectious-uveitis/ Wed, 29 Apr 2026 14:28:58 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-baricitinib-for-patients-with-refractory-non-infectious-uveitis/ This clinical trial is focused on studying the effectiveness and safety of a medication called baricitinib in treating a specific eye condition known as non-infectious non-anterior uveitis. This condition involves inflammation in parts of the eye that are not at the front and is not caused by an infection. The trial is particularly interested in cases where the condition has not improved with other treatments, specifically two types of biological therapies, which are advanced treatments that target specific parts of the immune system.

The purpose of the study is to evaluate how well baricitinib, which is a type of medication known as a JAK inhibitor, works in managing this challenging eye condition. Participants in the study will take baricitinib in the form of film-coated tablets, either 2 mg or 4 mg, taken orally. The study will also involve the use of other medications, such as prednisone, a type of steroid, and fluorescein sodium, which is used in eye examinations. Some participants may receive a placebo, which looks like the real medication but does not contain the active ingredient.

Throughout the study, participants will be monitored over a period of six months to assess changes in their condition. This will include regular eye examinations to check for improvements in inflammation and other symptoms. The study aims to see if baricitinib can help reduce the need for other medications, like steroids, and improve overall eye health. Participants will have their vision and eye inflammation checked at various points during the study to track any changes and improvements.

]]> Study Comparing Adalimumab and Mycophenolate Mofetil for Patients with Steroid-Dependent Non-Infectious Uveitis https://clinicaltrials.eu/trial/study-comparing-adalimumab-and-mycophenolate-mofetil-for-patients-with-steroid-dependent-non-infectious-uveitis/ Wed, 29 Apr 2026 14:26:24 +0000 https://clinicaltrials.eu/trial/study-comparing-adalimumab-and-mycophenolate-mofetil-for-patients-with-steroid-dependent-non-infectious-uveitis/ This clinical trial is focused on studying a condition called non-infectious uveitis, which is an inflammation of the middle layer of the eye. The study is specifically looking at cases where the inflammation is dependent on steroids, a type of medication often used to reduce inflammation. The trial will compare the effectiveness and safety of two treatments: adalimumab, which is given as an injection, and mycophenolate mofetil, which is taken as a tablet. The purpose of the study is to see which treatment works better for managing this eye condition.

Participants in the study will receive either adalimumab or mycophenolate mofetil over a period of 36 weeks. Adalimumab will be administered as an injection under the skin, starting with a higher dose on the first day, followed by regular doses every two weeks. Mycophenolate mofetil will be taken orally every day. Some participants may also receive a placebo, which looks like the real medication but does not contain any active ingredients. The study will monitor the participants’ eye health and any side effects they may experience during this time.

The trial aims to determine how well each treatment can control the inflammation in the eye and reduce the need for steroids. It will also assess the safety of the treatments by tracking any adverse effects. The study will last until 2027, with regular check-ups to evaluate the participants’ progress and the effectiveness of the treatments. This research could help improve treatment options for people with non-infectious uveitis who rely on steroids to manage their condition.

]]>